Lipocine (LPCN)

Lipocine (LPCN) Stock Price & Analysis


LPCN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.30 - $15.64
Previous Close$4.46
Average Volume (3M)28.43K
Market Cap
Enterprise Value-$5.65M
Total Cash (Recent Filing)$28.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-2.1
Aug 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding88,510,791
10 Day Avg. Volume23,339
30 Day Avg. Volume28,434
Standard Deviation0.23
Financial Highlights & Ratios
Price to Book (P/B)12.66
Price to Sales (P/S)7177.42
Price to Cash Flow (P/CF)-25.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.18
Enterprise Value/Gross Profit-11.30
Enterprise Value/Ebitda0.46
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $3.30 and its highest was $15.64 in the past 12 months.
    What is Lipocine’s market cap?
    Currently, no data Available
    When is Lipocine’s upcoming earnings report date?
    Lipocine’s upcoming earnings report date is Aug 09, 2023 which is in 62 days.
      How were Lipocine’s earnings last quarter?
      Lipocine released its earnings results on May 11, 2023. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.425 by -$0.255.
        Is Lipocine overvalued?
        According to Wall Street analysts Lipocine’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Lipocine pay dividends?
          Lipocine does not currently pay dividends.
          What is Lipocine’s EPS estimate?
          Lipocine’s EPS estimate is -$0.64.
            How many shares outstanding does Lipocine have?
            Lipocine has 5,206,517 shares outstanding.
              What happened to Lipocine’s price movement after its last earnings report?
              Lipocine reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.425. Following the earnings report the stock price went up 7.08%.
                Which hedge fund is a major shareholder of Lipocine?
                Currently, no hedge funds are holding shares in LPCN


                Lipocine Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description


                Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.


                Top 5 ETFs holding LPCN

                Market Value
                Smart Score
                iShares Core S&P Total U.S. Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold LPCN. The ETFs are listed according to market value of LPCN within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Intra-Cellular Therapies
                Eton Pharmaceuticals
                Kala Pharmaceuticals
                Cassava Sciences

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis